학술논문
JAK2/IDH-mutant–driven myeloproliferative neoplasm is sensitive to combined targeted inhibition
Document Type
Article
Author
McKenney, A.S.; Hanasoge Somasundara, A.V.; Spitzer, B.; Ahn, J.; Shank, K.; Papalexi, E.; Shih, A.H.; Rampal, R.; Levine, R.L.; Lau, A.N.; Vander Heiden, M.G.; Intlekofer, A.M.; Rapaport, F.T.; Patel, M.A.; Chiu, A.; Teruya-Feldstein, J.; Freinkman, E.; Akbay, E.A.; Wong, K.-K.; Steadman, M.; Nagaraja, R.; Yen, K.; Thompson, C.B.
Source
In: Journal of Clinical Investigation . (Journal of Clinical Investigation, 1 February 2018, 128(2):789-804)
Subject
Language
English
ISSN
15588238
00219738
00219738